EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the immunogenicity of a DNA vaccine for Leishmania major based on the Leishmania -activated C kinase antigen using calcium phosphate and chitosan adjuvants

Abdolaziz Gharaei, Mahmoud Rahdar iD, Oghlniaz Jorjani, Sedigheh Saberi, Molouk Beiromvand, Mohammad Hossein Feiz-Haddad

Transactions of The Royal Society of Tropical Medicine and Hygiene · 2025

DOI: 10.1093/trstmh/trae126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transactions of The Royal Society of Tropical Medicine and Hygiene, 2025. Verfasst von Abdolaziz Gharaei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infecti ous and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 15794-61357, Ir…. Hauptthemen laut MEDLINE: Vaccines, DNA, Chitosan, Calcium Phosphates, Leishmania major. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leishmaniasis represents a significant parasitic disease with global health implications, and the development of an affordable and effective vaccine could provide a valuable solution. This study aimed to evaluate the immunogenicity of a DNA vaccine targeting Leishmania major specifically based on the Leishmania-activated C kinase (LACK) antigen, utilizing calcium phosphate nanoparticles (CaPNs) and chitosan nanoparticles (ChitNs) as adjuvants.

Methods

Seventy female BALB/c mice, aged 4–6 wk and weighing 20–22 g, were selected and divided into five groups, each consisting of 14 mice. The first group received the plasmid LACK vaccine (pcDN3+LACK), the second group received the pcDN3+LACK vaccine with the CaPN adjuvant (pcDN3+LACK+CaPN), the third group received the pcDN3+LACK vaccine with the ChitN adjuvant (pcDN3+LACK+ChitN), the fourth group was administered phosphate-buffered saline as a negative control and the fifth group did not receive any vaccine, serving as a positive control. The vaccination program involved two intramuscular injections at 3-wk intervals. Three weeks following the final vaccination, the mice were challenged with wild-type L. major promastigotes via intradermal injection at the base of their tails. Clinical signs and lesion sizes were evaluated biweekly using Vernier calipers. Immune responses, including levels of interferon-gamma (IFN-γ) and interleukin-4 (IL-4), were assessed using ELISA.

Results

The groups receiving pcDN3+LACK+ChitN, pcDN3+LACK+CaPN and pcDN3+LACK exhibited the highest increases in IFN-γ titers and the most significant reductions in IL-4 titers. Furthermore, lesion sizes associated with Leishmania infection were reduced in the vaccinated groups, with the most favorable outcomes observed in the pcDN3+LACK+ChitN group.

Conclusions

These findings suggest that vaccination utilizing the LACK antigen in conjunction with CaPN and ChitN adjuvants may represent an effective strategy for the control of cutaneous leishmaniasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, DNAChitosanCalcium PhosphatesLeishmania majorLeishmaniasis, CutaneousAntigens, ProtozoanLeishmaniasis VaccinesProtozoan ProteinsAnimalsFemaleMiceMice, Inbred BALB CAdjuvants, ImmunologicNanoparticlesImmunogenicity, Vaccine

Stichwörter der Autor:innen

DNA vaccineLACKleishmaniasisnano-adjuvants

Substanzen

Vaccines, DNAChitosanCalcium Phosphatescalcium phosphateAntigens, ProtozoanAdjuvants, ImmunologicLeishmaniasis VaccinesLACK antigen, LeishmaniaProtozoan Proteins

Autor:innen und Institutionen

  • Infecti ous and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 15794-61357, Iran.
  • Department of Medical Parasitology, Medical school, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran.
  • Department of Medical Parasitology, Medical school, Golestan University of Medical Sciences, Gorgan 4918936316, Iran.
  • Department of Medical Parasitology, Medical school, Isfahan University of Medical Sciences, Isfahan 8174623461, Iran.

ORCID-Profile: Mahmoud Rahdar

Förderung

  • Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Zitieren

APA

Gharaei, A., Rahdar, M., Jorjani, O., Saberi, S., Beiromvand, M., & Feiz-Haddad, M. H. (2025). Evaluation of the immunogenicity of a DNA vaccine for Leishmania major based on the Leishmania -activated C kinase antigen using calcium phosphate and chitosan adjuvants. Transactions of The Royal Society of Tropical Medicine and Hygiene. https://doi.org/10.1093/trstmh/trae126

Vancouver

Gharaei A, Rahdar M, Jorjani O, Saberi S, Beiromvand M, Feiz-Haddad MH. Evaluation of the immunogenicity of a DNA vaccine for Leishmania major based on the Leishmania -activated C kinase antigen using calcium phosphate and chitosan adjuvants. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2025. doi:10.1093/trstmh/trae126

BibTeX
@article{Gharaei2025,
  author = {Gharaei, Abdolaziz and Rahdar, Mahmoud and Jorjani, Oghlniaz and Saberi, Sedigheh and Beiromvand, Molouk and Feiz-Haddad, Mohammad Hossein},
  title = {Evaluation of the immunogenicity of a DNA vaccine for Leishmania major based on the Leishmania -activated C kinase antigen using calcium phosphate and chitosan adjuvants},
  journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
  year = {2025},
  doi = {10.1093/trstmh/trae126}
}
Kostenlos starten →